Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation

Area of Science:

• Immunology
• Oncology
• Cellular Biology

Background:

• Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are established treatments for breast cancer and are under investigation for other cancers.
• The role of CDK4/6 inhibition in modulating T cell responses, particularly CD8+ T cells, remains an area of active research.

Purpose of the Study:

• To investigate the impact of CDK4/6 inhibition on the activation, persistence, and memory formation of CD8+ T cells.
• To elucidate the molecular mechanisms underlying CDK4/6 inhibitor-mediated effects on T cells.

Main Methods:

• Treatment of mouse and human CD8+ T cells with CDK4/6 inhibitors.
• Assessment of T cell persistence and immunologic memory in mice.
• Gene expression analysis (including MXD4 and MYC) in CD8+ T cells.
• Single-cell transcriptional profiling and T-cell receptor clonotype tracking in human patients.

Main Results:

• CDK4/6 inhibition increased CD8+ T cell persistence and immunologic memory in mice.
• Upregulation of MXD4, a MYC regulator, was observed in both mouse and human CD8+ T cells following CDK4/6 inhibition.
• In human breast cancer patients, CDK4/6 inhibitor therapy increased CD8+ memory precursors and decreased MYC target gene expression.

Conclusions:

• CDK4/6 inhibition promotes a CD8+ T cell memory phenotype in both preclinical models and human patients with breast cancer.
• These findings suggest that CDK4/6 inhibitors could enhance long-term protective immunity and may be beneficial in neoadjuvant settings to improve T cell priming before immunotherapy.